These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29887325)

  • 1. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2018 Jul; 36(29):4362-4368. PubMed ID: 29887325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
    Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2020 Nov; 38(50):8032-8039. PubMed ID: 33121846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
    Chesson HW; Laprise JF; Brisson M; Markowitz LE
    J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
    Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
    Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
    Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic implications of HPV vaccination in the United States.
    Kim JJ; Goldie SJ
    N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States.
    Laprise JF; Chesson HW; Markowitz LE; Drolet M; Martin D; Bénard É; Brisson M
    Ann Intern Med; 2020 Jan; 172(1):22-29. PubMed ID: 31816629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
    Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE;
    MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
    Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
    Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States.
    Daniels V; Prabhu VS; Palmer C; Samant S; Kothari S; Roberts C; Elbasha E
    Hum Vaccin Immunother; 2021 Jul; 17(7):1943-1951. PubMed ID: 33427033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
    Jit M; Brisson M; Laprise JF; Choi YH
    BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.
    Kim JJ; Simms KT; Killen J; Smith MA; Burger EA; Sy S; Regan C; Canfell K
    PLoS Med; 2021 Mar; 18(3):e1003534. PubMed ID: 33705382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
    Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.